My Public Health Journey into Pharma

Wenny Lin, PhD, MPH PHCP Seminar, 04.24.2019



Disclaimer

The content and views expressed in this presentation are solely mine and are not representative of my current or past employers.

Penn and Journey into Public Health



2008 – PhD, Cell & Molecular Biology (Gene Therapy & Vaccines)











SCHOOL OF PUBLIC HEALTH

2009 – Master of Public Health (Quantitative Methods)



NATIONAL CANCER INSTITUTE Cancer Prevention Fellowship Program

Jefferson College of Population Health





FELLOWSHIP

Application and Program Information

SUMMER CURRICULUM

Courses, Lectures, and Faculty

COLLOQUIA

Scientific Lecture Series

ABOUT US

Who We Are and What We Are About

Search CPFP



The Cancer Prevention Fellowship Program is a multidisciplinary postdoctoral program that trains future leaders in the field of cancer prevention and control. Watch the CPFP Video that highlights unique features of the CPFP through testimonials from current fellows and alumni, remarks from the former director, and reflections from the Director of the Division of Cancer Prevention, NCI.

Postdoctoral Fellowship Program

Outstanding opportunities for cutting-edge research in the basic, guantitative, social and behavioral sciences, and in clinical cancer prevention, have been the hallmarks of the CPFP since its inception.

Description | Eligibility | Application Guidelines

The application period for the 2019 Cancer




Program Spotlight: Drs. Loomans-Kropp and Pierre-Victor



Current CPFP fellow Dr. Holli Loomans-Kropp, recently published a review in Precision Oncology titled "Cancer prevention and screening: the next step in the era of precision medicine." In February 2019, current CPFP fellow Dr. Dudith Pierre-Victor published a study, "Association of Nonadherence to Cancer Screening Examinations with Mortality from Unrelated Causes: A Secondary Analysis of the PLCO Cancer crooning Trial" in JAMA Internal Medicine Learn more about






- Dedicated training office
 - Teaching, grant writing
- PIs focused on research
 - No teaching
 - No grants
 - Mentoring?
- Lots of data and collaboration
- Access to program directors
- Stipend and benefits

- Grant ineligibility
- Fewer teaching opportunities
- Government restrictions on:
 - Travel
 - Political activities
 - Side projects/hustles
- Limited exposure of PIs to "outside world"

NATIONAL CANCER INSTITUTE


NIH

Cancer Prevention Fellowship Program




Prospective study of ultraviolet radiation exposure and risk of cancer in the United States. Int J Cancer. 2012 Sep 15; 131(6): E1015–E1023.






Measuring telomere length for the early detection of precursor lesions of esophageal squamous cell carcinoma. BMC Cancer. 2013; 13: 578.

NIH NATIONAL CANCER INSTITUTE Cancer Prevention Fellowship Program




Beta-diversity metrics of the upper digestive tract microbiome are associated with body mass index. Obesity (Silver Spring). 2015 Apr; 23(4): 862–869.





T cell receptor repertoire among women who cleared and failed to clear cervical human papillomavirus infection: An exploratory proof-of-principle study. PLoS One. 2018; 13(1): e0178167.

Considerations for post training



Applicable skills and experiences

Science

- Interdisciplinary science: epidemiology, molecular bio
- Technical skills: programming, large databases
- Evidence: publications/presentations

People


- Teams: research and non-research
- Collaborations: initiated and inherited
- Communications: multiple disciplines

Process

- Project management: timelines and budget
- Communication: emails, presentations, networking
- Deciphering and following regulations

Recent keywords: real world data, data science, machine learning, omics, data analytics on imaging, omics, and digital health data, informatics





What am I looking for now?

- Growth opportunities new expertise, challenges, relationships
- Manager focused on development/mentoring
- People management opportunities
- Culture of trust, flexibility, and effective use of technology

Public Health-relevant roles and activities

Development

--Clinical development--Safety / pharmacovigilance

-Literature reviews -Benefit-risk assessment -Natural history

studies

Medical Affairs

--Registries--Phase IV--Safety studies

-Patterns of care analyses

-Retrospective and prospective studies

Commercial


--Forecasting --HEOR

--Evidence synthesis

--Commercial insights analytics


-Comparative effectiveness -Modeling -Meta-analyses -Data mining






A Real-World Data Study to Evaluate Treatment Patterns, Clinical Characteristics and Survival Outcomes for First- and Second-Line Treatment in Locally Advanced and Metastatic Urothelial Cancer Patients in Germany. J Cancer. 2018; 9(8): 1337–1348.





Real-World Effectiveness of Chemotherapy in Elderly Patients With Metastatic Bladder Cancer in the United States. Bladder Cancer. 2018; 4(2): 227–238.






	Postindex events and milestone OS rates						
	3 mo	6 mo	9 mo	12 mo	15 mo	18 mo	24 mo
Atezolizumab, IMvigor210							
Patients with events, n	23	34	42	47	53	56	56
OS rate, %	78.4	68.0	60.3	55.5	49.3	45.4	45.4
95% CI	69.3-85.1	58.2-76.0	50.3-68.9	45.5-64.4	39.4-58.5	35.3-54.9	35.3-54.9
Carbo-based, VHA							
Patients with events, n	26	78	110	143	163	176	193
OS rate, %	92.4	75.4	63.3	49.5	41.2	36.0	27.0
95% CI	86.8-95.7	67.4-81.7	54.7-70.8	40.7-57.6	32.6-49.5	27.7-44.3	19.4-35.2

Comparative Effectiveness of Non-cisplatin First-line Therapies for Metastatic Urothelial Carcinoma: Phase 2 IMvigor210 Study Versus US Patients Treated in the Veterans Health Administration. Eur Urol Oncol.2019 Feb;2(1):12-20.

Just launched! www.womeninpharmacareers.com



Last thoughts and contact

